COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

Description

This is a randomized, open-label, initiative within the Mass General Brigham healthcare system testing two remote care strategies for optimizing the prescription of guideline-directed medical therapies in patients with heart failure, regardless of left ventricular ejection fraction (LVEF).

Conditions

Heart Failure

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a randomized, open-label, initiative within the Mass General Brigham healthcare system testing two remote care strategies for optimizing the prescription of guideline-directed medical therapies in patients with heart failure, regardless of left ventricular ejection fraction (LVEF).

COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

Condition
Heart Failure
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Documented diagnosis of heart failure (e.g., ICD-9 codes 428 ICD-10 codes I50 or Problem list in the electronic health record)
  • * Most recent EF assessed within the past 24 months
  • * Seen Mass General Brigham provider within the last 24 months
  • * English or Spanish speaking
  • * LVEF\<50% currently prescribed or intolerant to both ARNi and SGLT2i
  • * LVEF\>50% currently prescribed or intolerant to SGLT2i
  • * Systolic blood pressure (SBP) \<90 mmHg at last measure
  • * Current severe aortic stenosis or severe aortic insufficiency
  • * Known amyloid heart disease
  • * Group 1 pulmonary arterial hypertension on disease-specific therapies (e.g., Ambrisentan, Bosentan, Epoprostenol, Treprostinil, Iloprost)
  • * eGFR\<30 mL/min/1.73m2
  • * Active chemotherapy
  • * Receiving end-of-life care or hospice
  • * History of transplant, currently listed above status 4 or being evaluated for transplant
  • * Outpatient intravenous inotrope use
  • * Current use of a Ventricular Assist Device
  • * Physician's discretion as inappropriate for remote management program

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Brigham and Women's Hospital,

Study Record Dates

2025-06